We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seelos Therapeutics Inc | NASDAQ:SEEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0097 | -3.36% | 0.2793 | 0.2752 | 0.2834 | 0.3134 | 0.2705 | 0.2947 | 208,188 | 17:08:53 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 3.03 Material Modification to Rights of Security Holders.
On January 10, 2024, Seelos Therapeutics, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Articles of Incorporation, as amended (the “Articles”), to increase the number of authorized shares of common stock, par value $0.001 per share (“Common Stock”), to a total of 400,000,000.
On January 10, 2024, the Company filed a Certificate of Amendment to the Articles (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada to increase the number of authorized shares of Common Stock from 16,000,000 to 400,000,000. Any newly authorized shares of Common Stock were identical to the shares of Common Stock previously authorized and outstanding. The Certificate of Amendment did not alter the voting powers or relative rights of the Common Stock.
The Certificate of Amendment had no immediate dilutive effect on the proportionate voting power or other rights of the Company’s existing stockholders. To the extent any of the Company’s outstanding warrants, options or other convertible securities are exercised, or the Company issues additional shares of Common Stock in the future, the Company’s stockholders will experience dilution. Any future issuance of additional authorized shares of Common Stock may, among other things, dilute the earnings per share of the Common Stock and the equity and voting rights of those holding Common Stock at the time the additional shares are issued. Additionally, this potential dilutive effect may cause a reduction in the market price of the Common Stock.
The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, which is filed herewith as Exhibit 3.1 and incorporated herein by reference.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On January 10, 2024, the Company held the Special Meeting. At the Special Meeting, a total of 6,318,764 shares, or 66.02% of the Common Stock issued and outstanding as of the record date, were represented virtually or by proxy.
At the Special Meeting, the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on December 15, 2023, as supplemented by the Supplement to Proxy Statement, filed with the SEC on December 22, 2023.
Set forth below is a brief description of each matter voted upon at the Special Meeting and the voting results with respect to each matter.
Proposal No. 1: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to: (a) that certain Convertible Promissory Note No. 1 in the initial principal amount of $22,000,000 and due November 23, 2024, issued by the Company to Lind Global Asset Management V, LLC (“Lind Global”) on November 23, 2021, as amended on December 10, 2021, on February 8, 2023, on May 19, 2023 and September 30, 2023, (b) that certain securities purchase agreement, dated November 23, 2021, by and between the Company and Lind Global, and (c) that certain Letter Agreement, dated September 21, 2023, by and between the Company and Lind Global, as amended by that certain Amendment No. 4 to Convertible Promissory Note and Amendment to Letter Agreement, effective September 30, 2023, by and between the Company and Lind Global (the “Convertible Note Proposal”).
For | Against | Abstentions | Broker Non-Votes | |||||||||
3,005,989 | 698,838 | 1,051,469 | 1,562,468 |
Proposal No. 2: To approve an amendment to the Articles to increase the number of authorized shares of common stock to a total of 400,000,000 (the “Authorized Share Increase Proposal”).
For | Against | Abstentions | ||||||||
5,189,686 | 1,101,134 | 27,944 |
Proposal No. 3: To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve the Convertible Note Proposal and/or the Authorized Share Increase Proposal.
For | Against | Abstentions | ||||||||
5,284,077 | 984,296 | 50,391 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
3.1 | Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed January 10, 2024. |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Seelos Therapeutics, Inc. | ||
Date: January 10, 2024 | By: | /s/ Raj Mehra, Ph.D. |
Name: Raj Mehra, Ph.D. | ||
Title: Chief Executive Officer and President |
Business Entity - Filing Acknowledgement 01/10/2024 Work Order Item Number: W2024011000383-3390553 Filing Number: 20243748592 Filing Type: Amendment After Issuance of Stock Filing Date/Time: 1/10/2024 8:50:00 AM Filing Page(s): 2 Indexed Entity Information: Entity ID: C8119-1987 Entity Name: SEELOS THERAPEUTICS, INC. Entity Status: Active Expiration Date: None Commercial Registered Agent C T CORPORATION SYSTEM 701 S CARSON ST STE 200, Carson City, NV 89701, USA FRANCISCO V. AGUILAR Secretary of State DEPUTY BAKKEDAHL Deputy Secretary for Commercial Recordings STATE OF NEVADA OFFICE OF THE SECRETARY OF STATE Commercial Recordings Division 401 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7138 North Las Vegas City Hall 2250 Las Vegas Blvd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880 Fax (702) 486-2888 The attached document(s) were filed with the Nevada Secretary of State, Commercial Recording Division. The filing date and time have been affixed to each document, indicating the date and time of filing. A filing number is also affixed and can be used to reference this document in the future. Respectfully, FRANCISCO V. AGUILAR Secretary of State Page 1 of 1 Commercial Recording Division 401 N. Carson Street Exhibit 3.1 |
Certified Copy 1/10/2024 9:13:20 AM Work Order Number: W2024011000383 Reference Number: 20243748616 Through Date: 1/10/2024 9:13:20 AM Corporate Name: SEELOS THERAPEUTICS, INC. The undersigned filing officer hereby certifies that the attached copies are true and exact copies of all requested statements and related subsequent documentation filed with the Secretary of State’s Office, Commercial Recordings Division listed on the attached report. Document Number Description Number of Pages 20243748592 Amendment After Issuance of Stock 2 Certified By: Rene Richardson Certificate Number: B202401104256750 You may verify this certificate online at http://www.nvsos.gov Respectfully, FRANCISCO V. AGUILAR Nevada Secretary of State FRANCISCO V. AGUILAR Secretary of State DEPUTY BAKKEDAHL Deputy Secretary for Commercial Recordings STATE OF NEVADA OFFICE OF THE SECRETARY OF STATE Commercial Recordings Division 401 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7138 North Las Vegas City Hall 2250 Las Vegas Blvd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880 Fax (702) 486-2888 |
Filed in the Office of Secretary of State State Of Nevada Business Number C8119-1987 Filing Number 20243748592 Filed On 1/10/2024 8:50:00 AM Number of Pages 2 |
Cover |
Jan. 10, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 10, 2024 |
Current Fiscal Year End Date | --12-31 |
Entity File Number | 000-22245 |
Entity Registrant Name | Seelos Therapeutics, Inc. |
Entity Central Index Key | 0001017491 |
Entity Tax Identification Number | 87-0449967 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 300 Park Avenue |
Entity Address, Address Line Two | 2nd Floor |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10022 |
City Area Code | 646 |
Local Phone Number | 293-2100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value |
Trading Symbol | SEEL |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Seelos Therapeutics Chart |
1 Month Seelos Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions